

# Efficacy of a Relaxation Scenario in Virtual Reality for the Comorbid Symptoms of Anxiety and Asthenia in a General Hospital Setting: A Pilot Comparative Randomized Open-Label Study

Эффективность применения релаксационного сценария в технологии виртуальной реальности в отношении коморбидных симптомов тревоги и астении в условиях соматического стационара: пилотное сравнительное рандомизированное открытое исследование

doi: 10.17816/CP221

Original research

Taisiya Lepilkina<sup>1</sup>, Allan Beniashvili<sup>1</sup>,  
Roman Cheremin<sup>2</sup>, Natalya Malyukova<sup>2</sup>,  
Margarita Morozova<sup>1</sup>, Mikhail Bogdanov<sup>2</sup>,  
Denis Burminsky<sup>1</sup>, Sergei Potanin<sup>1</sup>,  
Svetlana Rodkina<sup>2</sup>, George Rupchev<sup>1</sup>, Margarita Eip<sup>2</sup>

<sup>1</sup> Mental Health Research Center, Moscow, Russia

<sup>2</sup> Speech Pathology and Neurorehabilitation Center, Moscow, Russia

Таисия Лепилкина<sup>1</sup>, Аллан Бениашвили<sup>1</sup>,  
Роман Черемин<sup>2</sup>, Наталья Мalyukova<sup>2</sup>,  
Маргарита Морозова<sup>1</sup>, Михаил Богданов<sup>2</sup>,  
Денис Бурминский<sup>1</sup>, Сергей Потанин<sup>1</sup>,  
Светлана Родкина<sup>2</sup>, Георгий Рупчев<sup>1</sup>,  
Маргарита Эип<sup>2</sup>

<sup>1</sup> ФГБНУ «Научный центр психического здоровья», Москва, Россия

<sup>2</sup> ГБУЗ «Центр патологии речи и нейрореабилитации ДЗМ», Москва, Россия

## ABSTRACT

**BACKGROUND:** Patients in general hospitals often display concomitant signs of mental maladjustment: low mood, anxiety, apathy, asthenia, all of which can have a negative impact on the course of the underlying disease and the recovery process. One of the non-pharmacological approaches that has gained wider acceptance in medical practice in recent years is the use of procedures based on virtual reality.

**AIM:** Assess the efficacy of the new domestic, virtual reality application Flow as relates to symptoms of anxiety and asthenia in patients undergoing inpatient treatment.

**METHODS:** The study was open-label and had a comparison group; the patients were assigned to the experimental or control group using a randomization table. The patients were assessed using the Spielberger State Anxiety Inventory; the Fatigue Symptom Rating Scale; the Well-being, Activity, Mood questionnaire; the Depression Anxiety Stress Scale; and the Clinical Global Impression Scale. Physical parameters were measured before and after each virtual reality session. The obtained data were statistically processed.

**RESULTS:** The study involved 60 patients. In 40 patients, the treatment program included a course of five daily relaxation sessions in virtual reality; the control group consisted of 20 patients, who were treated in accordance with the usual practice of the institution. The addition of virtual reality sessions to the standard treatment course yielded significant advantage in terms of affective symptoms reduction in patients both after a single session and as a result of undergoing the full course, and several days after its completion. The patients in the experimental group also showed a significant decrease in blood pressure after the sessions, and this was most pronounced in individuals who initially had elevated and high blood pressure.

**CONCLUSION:** The use of relaxation program courses in the virtual reality application Flow is an effective and promising means of non-pharmacological care for non-psychiatric inpatients showing symptoms of anxiety, apathy, depressive mood, as well as hypertension.

## **АННОТАЦИЯ**

**ВВЕДЕНИЕ:** Пациенты соматических стационаров нередко демонстрируют сопутствующие признаки психической дезадаптации — сниженное настроение, тревогу, апатию, астению, которые могут оказывать негативное влияние на течение основного заболевания и процессы восстановления. Одним из нелекарственных подходов, в последние годы все шире внедряемых в медицинскую практику, является использование методик на основе технологии виртуальной реальности.

**ЦЕЛЬ:** Оценить эффективность нового отечественного приложения виртуальной реальности Flow в отношении симптомов тревоги и астении у пациентов, проходящих стационарное лечение.

**МЕТОДЫ:** Исследование было открытым, с группой сравнения; определение пациента в экспериментальную либо контрольную группу происходило с использованием рандомизационной таблицы. Состояние пациентов оценивалось при помощи шкалы ситуативной тревожности Спилбергера, шкалы оценки симптома усталости, опросника «Самочувствие, активность, настроение», шкалы депрессии, тревоги, стресса и шкал общего клинического впечатления. До и после каждой сессии виртуальной реальности проводилось измерение физикальных показателей. Полученные данные обрабатывались статистически.

**РЕЗУЛЬТАТЫ:** В исследовании приняли участие 60 пациентов. У 40 пациентов в программу лечения был включен курс из пяти ежедневных релаксационных сессий в виртуальной реальности; контрольную группу составили 20 пациентов, которые проходили лечение в соответствии с рутинной практикой учреждения. Добавление к стандартному лечению курса сессий в виртуальной реальности создавало значимое преимущество в редукации у пациентов аффективных жалоб как после одного занятия, так и в результате прохождения курса и через несколько дней после его завершения. Пациенты экспериментальной группы также демонстрировали достоверное снижение показателей артериального давления после прохождения сессий, причем наиболее выраженным оно было у лиц с изначально повышенным и высоким давлением.

**ЗАКЛЮЧЕНИЕ:** Курсовое использование релаксационной программы в технологии виртуальной реальности Flow является эффективным и перспективным методом нелекарственной помощи пациентам соматического стационара в отношении жалоб на тревогу, апатию, снижение настроения, а также симптомов гипертонии.

**Keywords:** *virtual reality; non-pharmacological therapy; comorbid mental symptoms; maladjustment reaction; lowering blood pressure*

**Ключевые слова:** *виртуальная реальность; нефармакологическая терапия; коморбидные психические симптомы; реакция дезадаптации; снижение артериального давления*

## INTRODUCTION

Physical illnesses are often accompanied by signs of stress and maladjustment, in the form of depressed mood and increased anxiety. It is reported that 18–33% of patients who have suffered a stroke also suffered from depression [1]; anxiety symptoms occur in 28% of non-psychiatric inpatients, and 8% meet the criteria for some anxiety disorder [2]. Affective symptoms and medical disorders have a compounding negative impact that manifests through psychological, behavioral, and physiological mechanisms. Anxiety and low mood may be a patient's reaction to disease, and a negative assessment of the prospects for recovery may limit that patient's usual activity and social circle; in turn, a physical illness can exacerbate the manifestations of an already existing mental disorder [3, 4]. Negative behavioral manifestations include addiction, sleep disorders, or violation of the treatment regimen [5]. Physiological mechanisms include increased inflammatory response and hypothalamic-pituitary-adrenal axis impairment [6]. Research also points to an association between anxiety disorders and hypertension [7]. Together, these factors can worsen the course and prognosis of the physical illness, reduce the effectiveness of treatment, and slow down recovery. Thus, the search for effective means of treatment of negative mental state is an important independent undertaking in the management of patients with physical illnesses.

The use of pharmacological resources for the treatment of comorbid symptoms of maladjustment, along with proven efficacy, has a number of limitations, such as an adverse increase in the pharmacological load; an often long period of effective dose selection; possible contraindications and side effects; and, for some drugs, the potential for addiction [8]. Non-pharmacological methods of treatment with comparable efficacy in such a context will have an advantage. Another traditional, and effective, form of care for various types of distress and maladjustment is psychotherapy. At the same time, data have been accumulating on the positive impact of different activities, such as meditation, yoga, various breathing practices, and mindfulness practices on the mental state [9, 10]. Literature suggests that meditation practices reduce stress levels and hypertension [11–13]. Studies also show that the regular use of meditation, relaxation, and breathing practices contributes to many positive changes in both the emotional state of those practicing them and aspects of their physical health,

such as a significant reduction in stress hormones [14] and markers of chronic inflammation [15], as well as normalization of elevated blood pressure (BP) [16–19].

In an attempt to achieve a standardization and reproducibility of these types of care, investigators and professionals are increasingly turning to technologies that are based on virtual reality. Virtual reality (VR) is a simulated three-dimensional immersive environment in which the user can act according to prearranged scenarios [20]. In recent years, various VR applications have found increasingly wide application in medical practice, including programs for both specialists (training of specific skills, simulation of medical processes, etc.) and patients (relaxation and stress management, overcoming anxiety, neurorehabilitation, etc.) [21–23]. According to the results of these studies, VR-based applications show a level of efficacy comparable to that of pharmacological, and, sometimes, even superior efficacy as a treatment means for anxiety disorders [24], phobias [25], eating disorders [26], and other psychopathological conditions. Such data justify the attempts being made to transfer relaxation practices to high-tech platforms. VR technologies allow, on the one hand, to standardize the procedure, and, on the other hand, they do not rule out the possibility of customizing the scenario, taking the patient's condition into account, selecting the optimal program duration, setting breathing parameters, preferred locations, as well as other parameters.

In Russia, Viartech Development LLC has developed the Flow relaxation program, integrated into a capsule chair, for people with various manifestations of a stress reaction, anxiety, or tension.

The main goal of this study was to evaluate the efficacy of the relaxation scenario in the VR Flow technology in relation to the symptoms of anxiety and asthenia in patients undergoing inpatient treatment. Study hypothesis: taking a course of sessions of a specially designed relaxation VR scenario, in addition to the primary therapy, should help reduce the severity of anxiety and affective symptoms.

## METHODS

### Study design

The study used an open-label design with a comparison group and simple randomization.

## Sample

The enrollment of study participants was carried out from March to June 2021 among patients of both sexes aged 18 to 68 years who were undergoing inpatient treatment at the Speech Pathology and Neurorehabilitation Center of the Moscow Healthcare Department.

The main inclusion criteria of the study were as follows:

- complaint of anxiety, bad mood, asthenia, tension, increased fatigue, and other manifestations of maladjustment;
- understanding of the study instructions and procedures, readiness and ability to sit through VR sessions, filling out of questionnaires and scales.

The exclusion criteria were as follows:

- severe cognitive, motor and/or speech impairments that prevent understanding of the instructions and limit one's ability to follow the study procedures;
- diagnosed epilepsy or a history of convulsive seizures;
- diagnosed mental illness (bipolar disorder, major depressive episode, schizophrenia, schizoaffective disorder, etc.);
- severe, decompensated or unstable physical illnesses.

## Enrollment and randomization

The study information leaflet informed the patients that it was not known in advance to which group (experimental or control) they would be assigned, and that that would be determined randomly. All patients in the comparison group could, if they so desired, undergo a course of VR after completing the program.

The participants were assigned to a particular group as follows: After inclusion of a new patient and the signing of an informed consent form, the clinical researcher called authors of the protocol who had no relation to the recruitment of patients in the study and did not come into direct contact with them. A randomization table was used to assign patients to groups; according to this table, each participant's serial number was randomly assigned a code of one of two groups: 40 codes for the VR group and 20 codes for the comparison group. After the clinical researcher at the site had received the group code for a new participant, this information became open to everybody.


The enrollment continued until an equal ratio of male and female patients in each group was achieved; data from patients included at the end of the recruitment who did not meet the target 1 : 1 sex distribution were removed

from the final analysis. In case of early withdrawal, the analysis included data collected at the time of exclusion. The primary ground for early withdrawal from the program was the end of hospitalization. The recruitment process is shown in Figure 1.

## Evaluation tools

The following procedures were used to assess the condition of patients:

1. Spielberger State Anxiety Inventory [27]. This is a questionnaire to assess the severity of state anxiety (as opposed to anxiety as a personality trait), consisting of 20 statements that must be assessed on a 4-point scale. The procedure adaptation by Yu. L. Khanin provides the following indicative standards: 20–34 means a low level of anxiety, 35–44 means a moderate level of anxiety, and above 46 means a high level of anxiety.
2. The Daily Fatigue Impact Scale (D-FIS) [28], consisting of 8 statements, was developed to assess the current state and daily changes in the symptom of fatigue associated with non-psychiatric illnesses. The patient rates each statement on a 5-point scale (0–4); a higher symptom severity corresponds to a higher total score.
3. The Well-being, Activity, Mood (WAM) questionnaire [29] explores three aspects of the current psycho-emotional state indicated in the title. The subject is asked to correlate his current well-being with the scale assessment between pairs of words describing the poles of one state (for example, cheerful-gloomy, tense-relaxed). The result is separate scores on the subscales of well-being (WAM-W), activity (WAM-A), and mood (WAM-M); the 30–50 range is the average (normal) level for each of them.
4. The Depression, Anxiety and Stress Scale (DASS-21) [30] is a questionnaire consisting of 21 statements to be ranked on a 4-point scale (0–3) for an assessment of the states of depression, anxiety, and stress experienced by the subject during the preceding week. The scale is not diagnostic; the concepts of stress, anxiety, and depression were used by the developers as a continuum to describe subjective experience. The final assessment in this test is the total score: the higher it is, the more pronounced the negative affective symptoms of the state.



**Figure 1. Participant flowchart.**

All of these scales are self-questionnaires and are filled in by patients on their own.

Clinical Global Impression Scale-Severity (CGI-S) and Clinical Global Impression Scale-Improvement (CGI-I) [31] are filled in by the clinical researcher. These are 7-point scales in which the doctor is asked to assess the severity of the patient’s condition as a whole (at the first visit) and the changes in the patient’s condition (at subsequent visits) in comparison with other patients with a similar diagnosis based on their clinical experience.

**Study procedures**

Patients of the experimental group underwent a relaxation VR session on a daily basis for five days. Physical parameters (pulse rate) were measured before and after each session. Filling of the scales and questionnaires

by the patient and patient’s condition assessment by the investigator were performed twice on the first day of the study (before and after the VR session), after the final (fifth, if the patient had not dropped out earlier) session, and five days after the end of the course. The total duration of the program thus amounted to 10 days (+2–5 days).

Patients in the control group underwent the same procedures, excluding VR sessions. On the first day, the interval between the first and subsequent measurements was about 6 hours.

All patients received standard pharmacotherapy, in accordance with the established diagnosis.

The following are the main outcomes of the study: the psychometric characteristics of patients in the experimental and control groups at the first examination;

changes in the estimated parameters as a result of a single VR session, after a course of five sessions and long-term, as well as a comparison of these data with the results of the control group; assessment of the statistical significance of the changes in parameters for each of the groups; and data on changes in physiological parameters as a result of VR-relaxation.

### Virtual reality scenario

All patients were given explanations about the upcoming VR sessions and their schedule by clinical researcher. To undergo the scenario, the patient was placed inside a specially equipped cocoon chair with a rotating bowl. Immediately before each relaxation session, the administrator of the VR capsule helped the participants to sit comfortably in the chair, fix the equipment (helmet, heart rate monitor), and provided support during the session.

The VR-program is a practice of guided relaxation, combining the methods of body therapy, hypnotherapy, work with negative emotional states and images. As part of the study, two virtual locations were used: a tropical beach and a mountainous landscape (Figure 2), which alternated uniformly for all participants in the study. The main characteristics that were taken into account when creating virtual locations were as follows: the practice space had to create a feeling of safety and comfort, be natural and at the same time cultivated, reflect the presence of the person in it, be filled and at the same time devoid of intense and stimulating elements that distract attention and interfere with focusing on internal processes. At the beginning and end of each session, the users assessed their state at the moment using a series of visual analog scales; they did this by placing a slider on these scales using the controller (joystick). The patients also noted the most pronounced emotions



Figure 2. Screenshots of Flow locations.

that they could detect in themselves at that moment. Depending on the assessments and responses of the patient, some stages of the practice were dynamically changed. Elements of scenario interactivity also included the ability to adjust some of the dynamic aspects of the scenario: the option to linger on one of the stages (for example, to better awareness of the ongoing processes), transition from one stage to the next.

One session took an average of 20 to 30 minutes, depending on the characteristics of the state indicated by the patient at the beginning of the scenario, and the preferred speed of navigation within it.

### **Description and technical characteristics of the equipment**

The following devices were used: a capsule chair for working in VR; a PC-based VR Oculus Rift S headset with built-in tracking; NZXT H1 650W computer with Intel Core i5-10600kf processor; Polar OH1 heart rate tracker; Samsung Galaxy Tab A7 32GB LTE (SM-T505N); Huawei e3372 modem.

### **Statistical analysis**

The obtained primary data were analyzed using the statistical software package Statistica 6.0, version for Windows (StatSoft Inc.).

Mean values (*M*) and standard deviation (*SD*) were used when processing the results. Deltas (the magnitude of changes in psychometric parameters compared to the baseline) were studied to compare the degree of psychological changes in the experimental and control groups. The significance of the differences between the groups at different stages of the study was assessed using the Mann–Whitney test (*p*). The Wilcoxon rank sum test (*p*) was used to assess the significance of the changes in each of the groups during the study. Differences were considered significant at the level of  $p < 0.05$ . The presence of a statistical relationship between the parameters was tested using the Spearman's rank correlation coefficient (*R*).

### **Ethics**

The study was approved by the ethics committee of the Speech Pathology and Neurorehabilitation Center of the Moscow Healthcare Department. Before participating in the study, all patients read the program information sheet and signed an informed consent form.

## **RESULTS**

The average age of the patients in the VR group (20 men and 20 women) was  $44.8 \pm 15.9$  years. The average age of the participants in the control group (10 men and 10 women) was  $39.0 \pm 14.7$  years. Differences in age between patients of the two groups were not statistically significant ( $p = 0.19$ ).

The study cohort consisted of patients with the following diagnoses (according to the International Classification of Diseases, 10th revision): 23 patients (38.3%) with stuttering (F98.5); 16 patients (26.7%) with other mental disorders due to damage to or dysfunction of the brain or due to physical illness (F06.x); 15 patients (25%) with personality and behavioral disorders due to illness, damage to and dysfunction of the brain (F07.x); 3 patients (5%) with sequelae of the COVID-19 coronavirus infection (U07.1) and other viral pneumonia (J12.8); 2 patients (3.3%) with somatoform autonomic dysfunction of respiratory organs (F45.38); and 1 patient (1.7%) with adjustment disorders (F43.2).

### **Baseline data**

At the first examination, patients in both groups demonstrated an average level of state anxiety (Spielberger State Anxiety Inventory), a high and very high level of anxiety on the DASS-21 scale, and average scores on the WAM scale. Patients from the VR group had a higher degree of state anxiety symptoms, manifestations of depression, stress (DASS-21), fatigue (D-FIS), and also characterized their well-being, activity, and mood (WAM scale) lower. However, significant differences were observed only for two parameters of the WAM questionnaire (lower assessments of well-being (WAM-W) and mood (WAM-M) in the VR group) (Table 1).

The average values of physiological parameters at the first measurement in the experimental group were as follows: systolic blood pressure,  $124.87 \pm 11.62$  mmHg; diastolic,  $79.37 \pm 10.32$  mmHg; pulse rate,  $70.87 \pm 12.34$  units.

### **Changes in scale parameters in the groups during the study (intergroup comparison)**

A single VR session led to a significant improvement in the well-being and mood of patients according to the WAM questionnaire, and it also reduced depression, anxiety, and stress according to the DASS-21 scale. After the final session of the VR course and five days after, the patients showed statistically significant positive changes in all studied psychometric parameters (Table 2).

**Table 1. Results of the psychometric assessment of patients at the first measurement (baseline),  $M\pm SD$** 

| Scale                               | Experimental group (VR) | Control group | Significance of differences, $p$ |
|-------------------------------------|-------------------------|---------------|----------------------------------|
| Spielberger State Anxiety Inventory | 42.93±11.43             | 39.45±9.87    | 0.28                             |
| DASS-21                             | 22.05±16.12             | 16.76±11.91   | 0.27                             |
| D-FIS                               | 12.05±9.31              | 7.01±4.29     | 0.22                             |
| WAM-W                               | 44.30±14.54             | 53.7±10.91    | 0.01*                            |
| WAM-A                               | 42.50±11.89             | 47.9±10.94    | 0.08                             |
| WAM-M                               | 48.28±13.88             | 56.05±11.07   | 0.02*                            |

Note: The asterisk (\*) marks the statistical significance of differences at  $p < 0.05$ .

**Table 2. Values of the scale parameters at time of visits and significance of changes ( $p$ ) compared with the first measurement in the VR group,  $M\pm SD$** 

| Scale                                 | First measurement (before the first VR session) | After the first VR session | $p$   | After a course of five VR sessions | $p$    | 5 days after completing the VR course | $p$     |
|---------------------------------------|---|----------------------------|-------|------------------------------------|--------|---------------------------------------|---------|
| Spielberger State Anxiety Inventory ↓ | 42.93±11.43                                     | 40.83±9.6                  | 0.94  | 39.05±9.45                         | 0.006* | 38.54±8.99                            | 0.026*  |
| DASS-21 ↓                             | 22.05±16.12                                     | 19.46±15.69                | 0.04* | 16.9±11.9                          | 0.01*  | 14.18±11.72                           | 0.009*  |
| D-FIS ↓                               | 12.05±9.31                                      | 10.65±8.62                 | 0.33  | 8.0±5.27                           | 0.003* | 6.94±4.76                             | 0.006*  |
| WAM-W ↑                               | 44.30±14.54                                     | 47.51±14.37                | 0.01* | 50.53±11.4                         | 0.007* | 51.67±12.52                           | 0.003*  |
| WAM-A ↑                               | 42.50±11.89                                     | 44.41±12.87                | 0.89  | 47.05±10.1                         | 0.03*  | 49.67±9.12                            | 0.0008* |
| WAM-M ↑                               | 48.28±13.88                                     | 50.33±13.58                | 0.04* | 53.03±10.05                        | 0.015* | 54.09±10.2                            | 0.023*  |

Note: The asterisk (\*) marks the statistical significance of differences at  $p < 0.05$ ; The arrows (↓) show the direction of the positive changes in the parameter.

In the control group, patients did not show significant changes in the studied parameters compared with the baseline assessment, with the exception of the DASS-21 score by the fifth day of the study. The table of average scale parameter values in the comparison group and the significance of the changes at the time of each visit is given in Table S1 in the Supplementary.

The dynamics of the studied parameters in the experimental and control groups during the study is graphically presented in Figures 3–6.

### Comparison of the degree of changes in psychometric parameters (intragroup changes)

Changes in the psychometric parameters compared to their baseline (delta) during the study in the experimental and control groups are presented in Table 3.


On the first day, there were no significant differences between the groups in terms of the changes in psychometric parameters; however, by the fifth day, significant differences were visible in the D-FIS score

(severity of the fatigue symptom): a more pronounced reduction in the symptom was observed in the group of patients who had undergone a course of relaxing VR sessions (Figure 7).

At the follow-up visit (five days after the completion of a course of five VR sessions), the experimental group showed significantly more pronounced positive changes according to the WAM questionnaire in terms of well-being and activity (Figure 8).


### Changes in physical parameters as a result of sessions of virtual reality

One of the objectives of the study was to investigate changes in the physical parameters (blood pressure and pulse rate) as a result of undergoing VR-relaxation. The average values of systolic, diastolic blood pressure and pulse rate before and after undergoing VR sessions are presented in Table 4 (after the first session) and in Table S2 in the Supplementary (after the second and subsequent sessions).




**Figure 3.** Changes in the Spielberger State Anxiety Inventory parameters in the experimental and control groups during the study.


*Note:* Designations here and in Figures 4–6: group code in study 1 — experimental group (VR), group code in study 2 — control group; 1.0 — baseline examination, 1.2 — assessment after the first VR session, 5.0 — assessment after a course of five VR sessions, 6.0 — assessment 5 days after the completion of the course of VR sessions in the experimental group and the corresponding points in the control group.



**Figure 4.** Changes in the DASS-21 parameters in the experimental and control groups during the study.



**Figure 5.** Changes in the D-FIS parameters in the experimental and control groups during the study.




**Figure 6.** Changes in the WAM parameters in the experimental and control groups during the study.


**Table 3. Changes in psychometric parameters and the significance of differences (*p*) between them in the experimental and control groups during the study, *M*±*SD***

| Scale                               | First day       |               | Fifth day        |               | Long-term         |               |
|-------------------------------------|-----------------|---------------|------------------|---------------|-------------------|---------------|
|                                     | VR group        | Control group | VR group         | Control group | VR group          | Control group |
| Spielberger State Anxiety Inventory | -2.1±7.36       | 0.1±4.56      | -3.82±7.55       | -0.65±6.73    | -3.67±8.02        | -0.38±6.31    |
|                                     | <i>p</i> =0.262 |               | <i>p</i> =0.194  |               | <i>p</i> =0.14    |               |
| DASS-21                             | -2.0±5.36       | -0.06±4.38    | -5.03±10.42      | -2.84±5.67    | -5.58±11.26       | -1.56±6.93    |
|                                     | <i>p</i> =0.256 |               | <i>p</i> =0.883  |               | <i>p</i> =0.466   |               |
| D-FIS                               | -1.4±4.6        | 1.0±3.78      | -3.9±6.89        | 0.95±3.89     | -3.73±6.68        | 0.006±4.44    |
|                                     | <i>p</i> =0.167 |               | <i>p</i> =0.023* |               | <i>p</i> =0.123   |               |
| WAM-W                               | 3.26±7.52       | 0.05±6.37     | 5.95±13.05       | 2.3±5.39      | 6.85±13.89        | -1.63±6.21    |
|                                     | <i>p</i> =0.191 |               | <i>p</i> =0.173  |               | <i>p</i> =0.0034* |               |
| WAM-A                               | 1.92±7.26       | -0.11±5.73    | 4.24±13.06       | 1.9±7.99      | 6.67±9.9          | -0.69±5.9     |
|                                     | <i>p</i> =0.185 |               | <i>p</i> =0.279  |               | <i>p</i> =0.014*  |               |
| WAM-M                               | 1.59±4.6        | 0.39±4.09     | 4.71±11.04       | 1.7±8.44      | 4.88±11.28        | 0.5±6.06      |
|                                     | <i>p</i> =0.389 |               | <i>p</i> =0.19   |               | <i>p</i> =0.207   |               |

Note: The asterisk (\*) marks the statistical significance of differences at *p* < 0.05.



**Figure 7. Changes in the D-FIS score between the first measurement and on the fifth day in the experimental (1) and control (2) groups.**  
 Note: The D-FIS score is an inverse scale: higher values mean greater symptom severity, so the lower the delta (visit 5 minus visit 1.1) the better.



**Figure 8. Changes in the WAM scale parameters between the first measurement and the final measurement in the experimental (1) and control (2) groups.**

**Table 4. Blood pressure and pulse rate before and after the first VR session (n=40) and the significance of changes (p), M±SD**

| Stage              | Blood pressure, mm Hg |             | Pulse rate, units |
|--------------------|-----------------------|-------------|-------------------|
|                    | systolic              | diastolic   |                   |
| Before the session | 124.87±11.62          | 79.37±10.32 | 70.87±12.34       |
| After the session  | 120.03±13.05          | 76.68±9.23  | 68.21±9.66        |
| p                  | 0.0008*               | 0.016*      | 0.0002*           |

Note: The asterisk (\*) marks the statistical significance of differences at  $p < 0.05$ .

There is a significant decrease in all parameters in most cases as a result of undergoing the VR program. The decrease in blood pressure was more pronounced in individuals with initially higher blood pressure. In a subgroup of 11 such patients at the final VR session (5 patients with high-normal blood pressure according to the World Health Organization classification of hypertension, 4 patients with grade I hypertension, 2 patients with grade II hypertension), the decrease in blood pressure was even more pronounced (Table 5).

It was also found that for patients with a systolic pressure of 130 or higher before the first VR session, a more pronounced blood pressure decrease after the VR session (at the first visit) meant more pronounced changes on the Spielberger State Anxiety Inventory; i. e., patients with high blood pressure simultaneously showed a reduction in both BP and anxiety ( $R=0.52$ ).

## DISCUSSION

### Main findings

The conducted study provides empirical confirmation of the efficacy of the VR relaxation scenario for patients with anxiety and bad mood in a hospital setting. Comparison of the psychometric parameters of patients who underwent a course of VR sessions with patients from the control group shows a clear advantage in terms of positive changes in the first group. There is a significant benefit that accumulates and remains after the completion

of the course in terms of improvement regarding anxiety, fatigue, bad mood, various aspects of well-being in the VR group, while patients in the control group showed no significant changes in these parameters throughout the entire study period. The psychological benefit of VR sessions was also reflected in the physiological parameters: blood pressure and pulse rate. Interestingly, the more pronounced the disorders at the beginning of the study were, the more significant the improvement in the patients' condition in terms of both their mental status and autonomic disorders proved.

### Strengths and limitations of the study

This study was the first study of the efficacy of the VR relaxation scenario Flow in a clinical sample. The positive aspects of the study also include the significant number of participants in the program, sufficient psychometric tools for pilot testing of the hypothesis put forward, and the presence of a comparison group. The study design allowed us to investigate the effects of not only a single VR session, but also the whole course, as well as the stability of the achieved improvement in patients. The limitations of the study are the clinical heterogeneity of the studied cohort of patients, the lack of consideration of the diagnosis impact and the contribution of the pharmacotherapy received by the participants to the observed changes.

### Comparison with the existing literature

A wide review of VR studies [32] published between 2000 and 2020 and indexed in major electronic databases (a total of 28 studies analyzed) confirms the effectiveness of using various programs based on VR technology for the treatment of many negative mental conditions, including post-traumatic stress disorder, specific phobias, and social anxiety.

A number of systematic reviews highlight the application of VR methods in a hospital setting. VR instruments have been shown to be effective in relieving pain and reducing

**Table 5. Blood pressure before and after the fifth VR session and the significance of the changes (p) in the subgroup of patients with elevated and high blood pressure (n=11)**

| Stage              | Blood pressure, mm Hg |             |
|--------------------|-----------------------|-------------|
|                    | systolic              | diastolic   |
| Before the session | 140.55±9.35           | 86.64±6.47  |
| After the session  | 124.63±11.96          | 80.27±12.23 |
| p                  | 0.003*                | 0.02*       |

Note: The asterisk (\*) marks the statistical significance of differences at  $p < 0.05$ .

preoperative anxiety in adult patients [33], as well as in a group of adolescent patients [34].

It should be noted that a significant portion of meta-analytical studies using VR technologies do not distinguish between the content of the software, taking into account both virtual games and 3D trips and programs developed specifically for certain therapeutic tasks, although it would seem reasonable to expect the effectiveness of the latter to be higher. In this sense, a direct correlation of the results of various studies may be, to some extent, incorrect from a methodological point of view.

The positive aspects of VR technology also usually include its good tolerance by patients, a high level of involvement of participants, and the possibility of reducing the drug load [35, 36]. Wide introduction of the technology at this stage is limited by the rather high cost of equipment and, to a greater extent, the lack of proven tools for solving specific therapeutic problems and the high costs of their development.

In general, the results of this study are consistent with those of other studies, which also show that the use of tools based on VR technology is effective in addressing various manifestations of anxiety and psychological distress.

The positive results obtained from the Flow pilot study allow us to be optimistic about the prospects of the VR platform in both clinical and outpatient practice. There could be future studies on other samples (including clinical ones) or new scenarios developed within the platform.

## CONCLUSION

The results of this study show that the use of the VR relaxation scenario Flow is an effective and promising tool for reducing anxiety and affective symptoms in non-psychiatric inpatients and can be recommended for inclusion in a care program in medical institutions.

### Article history:

**Submitted:** 28.10.2022

**Accepted:** 14.02.2023

**Published Online:** 16.03.2023

**Acknowledgments:** The authors express their gratitude to the employees of Viartech Development LLC: Flow project manager A.I. Konovalov for coordinating the study process; P.A. Dorofeev, A.V. Melnik, V.O. Konyakhin for

administration of the process of using the VR-capsule during the study; T.V. Kochneva, laboratory research assistant of the laboratory of psychopharmacology at the Mental Health Research Center, for participation in creating the electronic database; to the doctors and staff of the Speech Pathology and Neurorehabilitation Center of the Moscow Healthcare Department for help and feedback on the use of the VR-capsule in the treatment process.

**Authors' contribution:** T.A. Lepilkina: development of the study design and protocol, creation and statistical analysis of the database, writing the text of the manuscript; A.G. Beniashvili, R.A. Cheremin: setting objectives and development of the study design, discussing the results and drawing conclusions, editing the text of the manuscript; N.G. Malyukova: selection and inclusion of patients in the study, creation of the study groups, psychometric examination of patients, coordination of the study process; M.A. Morozova: development of the study design, analysis of the data obtained and editing of the text of the manuscript; M.A. Bogdanov, S.V. Rodkina, M.N. Eip: selection, inclusion and psychometric examination of patients; D.S. Burminsky, S.S. Potanin, G.E. Rupchev: analysis of the obtained data and editing of the text of the manuscript. All authors have made a significant contribution to the study and preparation of the article and have read and approved the final version before publication.

**Funding:** The research was carried out without additional funding.

**Conflict of interest:** The authors declare no conflicts of interest.

### Supplementary data

Supplementary material related to this article can be found in the online version at doi: 10.17816/CP221

### For citation:

Lepilkina TA, Beniashvili AG, Cheremin RA, Malyukova NG, Morozova MA, Bogdanov MA, Burminskiy DS, Potanin SS, Rodkina SV, Rupchev GE, Eip MN. Efficacy of a relaxation scenario in virtual reality for comorbid symptoms of anxiety and asthenia in a general hospital setting: a pilot comparative randomized open-label study. Consortium Psychiatricum. 2023; 4(1):CP221. doi: 10.17816/CP221

## Information about the authors

**\*Taisiya Alekseevna Lepilkina**, Cand. Sci (Psychol.), Scientist Researcher, Laboratory of Psychopharmacology, Mental Health Research Center; ORCID: <https://orcid.org/0000-0002-2640-4658>, Scopus Author ID: 35773329800, E-mail: [lepilkina@hotmail.com](mailto:lepilkina@hotmail.com)

**Allan Gerovich Beniashvili**, Cand. Sci (Med.), Senior Research Officer, Laboratory of Psychopharmacology, Mental Health Research Center; ORCID: <https://orcid.org/0000-0002-5149-3760>, e-Library SPIN-code: 2223-0991, Scopus Author ID: 56337096600

**Roman Avenirovich Cheremin**, Cand. Sci (Med.), Director of Speech Pathology and Neurorehabilitation Center of the Moscow Healthcare Department; ORCID: <https://orcid.org/0000-0001-6018-6327>, e-Library SPIN-code: 6480-9096

**Natalya Georgievna Malyukova**, Cand. Sci (Psychol.), Head of the Department of Medical Psychology, Speech Pathology and Neurorehabilitation Center of the Moscow Healthcare Department; ORCID: <https://orcid.org/0000-0003-1142-0804>, e-Library SPIN-code: 7578-9524

**Margarita Alekseevna Morozova**, Dr. Sci (Med.), Professor, Head of the Laboratory of Psychopharmacology, Mental Health Research Center; ORCID: <https://orcid.org/0000-0002-7847-2716>, e-Library SPIN-code: 6162-5816, Scopus Author ID 7006920838, ResearcherId: D-9098-2015

**Mikhail Alexandrovich Bogdanov**, Medical Psychologist, Speech Pathology and Neurorehabilitation Center of the Moscow Healthcare Department; ORCID: <https://orcid.org/0000-0002-5033-7221>

**Denis Sergeevich Burminsky**, Cand. Sci (Med.), Senior Researcher, Laboratory of Psychopharmacology, Mental Health Research Center; ORCID: <https://orcid.org/0000-0001-7098-2570>, e-Library SPIN-code: 4895-9352, Scopus Author ID: 6299707400, ResearcherId: S-1759-2016

**Sergei Sergeevich Potanin**, Cand. Sci (Med.), Senior Research Officer, Laboratory of Psychopharmacology, Mental Health Research Center; ORCID: <https://orcid.org/0000-0002-9180-1940>, e-Library SPIN-code: 3817-9217, Scopus Author ID: 56010445300, ResearcherId: L-1455-2016

**Svetlana Vladimirovna Rodkina**, Medical Psychologist, Speech Pathology and Neurorehabilitation Center of the Moscow Healthcare Department; ORCID: <https://orcid.org/0000-0002-0478-1380>

**George Evgenievich Rupchev**, Cand. Sci (Psychol.), Scientist Researcher, Laboratory of Psychopharmacology, Mental Health Research Centre; ORCID: <https://orcid.org/0000-0002-4440-095X>, e-Library SPIN-code: 8523-1306, Scopus Author ID: 30267946900, ResearcherId: B-4229-2015

**Margarita Nikolaevna Eip**, Medical Psychologist, Speech Pathology and Neurorehabilitation Center of the Moscow Healthcare Department; ORCID: <https://orcid.org/0000-0001-8666-5019>

\*corresponding author

## References

1. Medeiros GC, Roy D, Kontos N, Beach SR. Post-stroke depression: a 2020 updated review. *Gen Hosp Psychiatry*. 2020;66:70-80. doi: 10.1016/j.genhosppsy.2020.06.011.
2. Walker J, van Niekerk M, Hobbs H, et al. The prevalence of anxiety in general hospital inpatients: a systematic review and meta-analysis. *Gen Hosp Psychiatry*. 2021;72:131-40. doi: 10.1016/j.genhosppsy.2021.08.004.
3. Janeczek P. Coexistence of mental and somatic diseases and difficulties in diagnosis and working with mentally ill people. *J Educ Health Sport*. 2022;12(7):649-59. doi: 10.12775/JEHS.2022.12.07.065.
4. Sikter A. Hypocapnia and mental stress can trigger vicious circles in critically ill patients due to energy imbalance: a hypothesis presented through cardiogenic pulmonary oedema. *Neuropsychopharmacol Hung*. 2018;20(2):65-74.
5. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. *Arch Intern Med*. 2000;160(14):2101-7. doi: 10.1001/archinte.160.14.2101.
6. Sobel RM, Markov D. The impact of anxiety and mood disorders on physical disease: the worried not-so-well. *Curr Psychiatry Rep*. 2005;7(3):206-12. doi: 10.1007/s11920-005-0055-y.
7. Johnson HM. Anxiety and hypertension: is there a link? A literature review of the comorbidity relationship between anxiety and hypertension. *Curr Hypertens Rep*. 2019;21(9):66. doi: 10.1007/s11906-019-0972-5.
8. Michelini S, Cassano GB, Frare F, Perugi G. Long-term use of benzodiazepines: tolerance, dependence and clinical problems in anxiety and mood disorders. *Pharmacopsychiatry*. 1996;29(4):127-34. doi: 10.1055/s-2007-979558.
9. Jain S, Shapiro SL, Swanick S, et al. A randomized controlled trial of mindfulness meditation versus relaxation training: effects on distress, positive states of mind, rumination, and distraction. *Ann Behav Med*. 2007;33(1):11-21. doi: 10.1207/s15324796abm3301\_2.
10. Barrett CJ. Mindfulness and rehabilitation: teaching yoga and meditation to young men in an alternative to incarceration program. *Int J Offender Ther Comp Criminol*. 2017;61(15):1719-38. doi: 10.1177/0306624X16633667.
11. Amarasekera AT, Chang D. Buddhist meditation for vascular function: a narrative review. *Integr Med Res*. 2019;8(4):252-6. doi: 10.1016/j.imr.2019.11.002.
12. Anderson JW, Liu C, Kryscio RJ. Blood pressure response to transcendental meditation: a meta-analysis. *Am J Hypertens*. 2008;21(3):310-6. doi: 10.1038/ajh.2007.65.
13. Geiger C, Cramer H, Dobos G, Kohl-Heckl WK. A systematic review and meta-analysis of mindfulness-based stress reduction for arterial hypertension. *J Hum Hypertens*. 2022. doi: 10.1038/s41371-022-00764-z.
14. Prakhinkit S, Suppakitporn S, Tanaka H, Suksom D. Effects of Buddhism walking meditation on depression, functional fitness, and endothelium-dependent vasodilation in depressed elderly. *J Altern Complement Med*. 2014;20(5):411-6. doi: 10.1089/acm.2013.0205.
15. Pascoe MC, Thompson DR, Jenkins ZM, Ski CF. Mindfulness mediates the physiological markers of stress: systematic review and meta-analysis. *J Psychiatr Res*. 2017;95:156-78. doi: 10.1016/j.jpsychires.2017.08.004.
16. Ponte Márquez PH, Feliu-Soler A, Solé-Villa MJ, et al. Benefits of mindfulness meditation in reducing blood pressure and stress in patients with arterial hypertension. *J Hum Hypertens*. 2019;33(3):237-47. doi: 10.1038/s41371-018-0130-6.
17. Shi L, Zhang D, Wang L, et al. Meditation and blood pressure: a meta-analysis of randomized clinical trials. *J Hypertens*. 2017;35(4):696-706. doi: 10.1097/HJH.0000000000001217.

18. Barnes VA, Pendergrast RA, Harshfield GA, Treiber FA. Impact of breathing awareness meditation on ambulatory blood pressure and sodium handling in prehypertensive African American adolescents. *Ethn Dis.* 2008;18(1):1-5.
19. Adams ZW, Sieverdes JC, Brunner-Jackson B, et al. Meditation smartphone application effects on prehypertensive adults' blood pressure: dose-response feasibility trial. *Health Psychol.* 2018;37(9):850-60. doi: 10.1037/hea0000584.
20. Liaw SY, Choo T, Wu LT, et al. "Wow, woo, win" — healthcare students' and facilitators' experiences of interprofessional simulation in three-dimensional virtual world: a qualitative evaluation study. *Nurse Educ Today.* 2021;105:105018. doi: 10.1016/j.nedt.2021.105018.
21. Zhang M, Ding H, Naumceska M, Zhang Y. Virtual reality technology as an educational and intervention tool for children with autism spectrum disorder: current perspectives and future directions. *Behav Sci (Basel).* 2022;12(5):138. doi: 10.3390/bs12050138.
22. Taneja A, Vishal SB, Mahesh V, Geethanjali B. Virtual reality based neuro-rehabilitation for mental stress reduction. In: 2017 fourth international conference on signal processing, communication and networking (ICSCN); 2017 March 16-18; Chennai, India. IEEE; 2017. p. 1-5. doi: 10.1109/ICSCN.2017.8085665.
23. Georgiev DD, Georgieva I, Gong Z, et al. Virtual reality for neurorehabilitation and cognitive enhancement. *Brain Sci.* 2021;11(2):221. doi: 10.3390/brainsci11020221.
24. Carl E, Stein AT, Levihn-Coon A, et al. Virtual reality exposure therapy for anxiety and related disorders: a meta-analysis of randomized controlled trials. *J Anxiety Disord.* 2019;61:27-36. doi: 10.1016/j.janxdis.2018.08.003.
25. Wechsler TF, Kümpers F, Mühlberger A. Inferiority or even superiority of virtual reality exposure therapy in phobias? — A systematic review and quantitative meta-analysis on randomized controlled trials specifically comparing the efficacy of virtual reality exposure to gold standard in vivo exposure in agoraphobia, specific phobia, and social phobia. *Front Psychol.* 2019;10:1758. doi: 10.3389/fpsyg.2019.01758.
26. Clus D, Larsen ME, Lemey C, Berrouguet S. The use of virtual reality in patients with eating disorders: systematic review. *J Med Internet Res.* 2018;20(4):e157. doi: 10.2196/jmir.7898.
27. Khanin YuL. *Kratkoe rukovodstvo k shkale reaktivnoi i lichnostnoi trevozhnosti Ch.D. Spilbergera.* Leningrad: LNIIFK; 1976. 40 p. Russian.
28. Fisk JD, Doble SE. Construction and validation of a fatigue impact scale for daily administration (D-FIS). *Qual Life Res.* 2002;11(3):263-72. doi: 10.1023/a:1015295106602.
29. Burlachuk LF, Morozov SM. *Slovar'-spravochnik po psikhodiagnostike.* 2nd ed. Saint Petersburg: Piter; 2003. 528 p. Russian.
30. Lovibond SH, Lovibond PF. *Manual for the depression anxiety stress scales.* 2nd ed. Sydney: Psychology Foundation of Australia; 1995. 42 p.
31. Guy W. *ECDEU assessment manual for psychopharmacology.* Rockville: US department of health and human services, public health service, alcohol drug abuse and mental health administration, NIMH, psychopharmacology research branch; 1976. 028 Clinical global impressions (CGI); p. 218-22.
32. Donnelly MR, Reinberg R, Ito KL, et al. Virtual reality for the treatment of anxiety disorders: a scoping review. *Am J Occup Ther.* 2021;75(6):7506205040. doi: 10.5014/ajot.2021.046169.
33. Smith V, Warty RR, Sursas JA, et al. The effectiveness of virtual reality in managing acute pain and anxiety for medical inpatients: systematic review. *J Med Internet Res.* 2020;22(11):e17980. doi: 10.2196/17980.
34. Ridout B, Kelson J, Campbell A, Steinbeck K. Effectiveness of virtual reality interventions for adolescent patients in hospital settings: systematic review. *J Med Internet Res.* 2021;23(6):e24967. doi: 10.2196/24967.
35. Saposnik G, Cohen LG, Mamdani M, et al.; Stroke outcomes research Canada. efficacy and safety of non-immersive virtual reality exercising in stroke rehabilitation (EVREST): a randomised, multicentre, single-blind, controlled trial. *Lancet Neurol.* 2016;15(10):1019-27. doi: 10.1016/S1474-4422(16)30121-1.
36. Sarkar U, Lee JE, Nguyen KH, et al. Barriers and facilitators to the implementation of virtual reality as a pain management modality in academic, community, and safety-net settings: qualitative analysis. *J Med Internet Res.* 2021;23(9):e26623. doi: 10.2196/26623.